TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06041620

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGB-Ex01
Description: CRISPR-Cas12b editing hematopoietic stem cells
Study: NCT06315842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Levels of Diagnostic and Therapeutic Intervention tool by Fontecha and col.
Description: During the intervention periods, participating physicians will integrate into their usual clinical practice a tool for adjusting diagnostic and therapeutic intensity designed by Fontecha-Gómez and colleagues. The tool for adjusting the level of diagnostic and therapeutic intensity classifies patients' profiles into 5 groups based on the recommended level of adjustment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual clinical practice
Description: The participating physicians will carry out the standard clinical practice currently performed in the study centers. This means that during this period, the diagnostic and therapeutic adjustment tool or any similar tool will not be introduced into routine clinical practice.
Study: NCT04752020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic
Description: Use of netarsudil after Descemetorhexis without endothelial keratoplasty
Study: NCT05880940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boost - Moveable Wheelchair Armrest
Description: The movable wheelchair arm rest device is a novel wheelchair armrest that quickly clicks into a manual wheelchair frame just like a conventional armrest. However, unlike a conventional armrest, the movable wheelchair arm rest device allows users to activate arm muscles in a way that is appropriate for the early stages of stroke recovery and consistent with the Feys et al. rocking chair approach: with biomechanical support of the shoulder, without high cognitive demand, and focusing on the out-of-synergy movement pattern that requires elbow extension. For the study, the investigators ask participants to exercise using Boost for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Arm and Hand Exercise Program
Description: These exercises will be assigned to the participants electronically using a commercial home exercise program platform commonly used by hospital systems (i.e.: Medbridge). They will be encouraged to exercise for 30 min/day in addition to the regular rehabilitation therapy at ARU. These exercises will be monitored and supervised by therapists who have been trained in the study protocol. Once participants are discharged from the unit, they will be allowed to keep the electronic exercise program until their 3-month post stroke follow up visit, the last visit of the study. For this study, the investigators ask participants to exercise following this customized arm and hand exercise program for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit.
Study: NCT05119621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS application
Description: Assigned Interventions: In addition to the standard pain management applied in the clinic, TENS will be applied to children who have had surgery.
Study: NCT06428487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolgolimab
Description: Prolgolimab infusions 1 mg/kg
Study: NCT05839041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVD-104
Description: Intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVD-104
Description: Intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVD-104
Description: Intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avacincaptad
Description: Intravitreal injection of 2 mg avacincaptad
Study: NCT06286254

Intervention type: DRUG
Intervention: Cycloferone
Description: Cycloferone® is administered according to the instruction for medical use: 600 mg (4 tablets) once daily on day 1, 2, 4, 6 and 8.
Study: NCT05908344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activated Sleep Pad system (Frequen-ZZZ)
Description: The investigational device is a sleep pad and bedside controller system capable of producing a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a powered device experiences its specific area of effect. The field potentials generated by the pad are hypothesized to have benefit for sleep.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deactivated Sleep Pad system (Frequen-ZZZ)
Description: The investigational device is a sleep pad and bedside controller system that produces a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a non-powered device experiences all functional aspects of the device except the intended magnetic field potential that is hypothesized to have benefit for sleep.
Study: NCT04979052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Gamma-1B
Description: 100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.
Study: NCT06506565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Infusion during wound care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: Infusion during wound care
Study: NCT05891353

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Water Immersion
Description: Cold Water Immersion task of hand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Inducing Stretch
Description: Moderately painful stretch of the neck

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Free Stretch
Description: Pain free stretch of the neck
Study: NCT05493761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 60 mg (1ml) administered subcutaneously once every 6 months for 12 months (totally 2 injections). Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate Sodium
Description: 70 mg (1 tablet) administered per os once weekly for 12 months. Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
Study: NCT06631430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3810477
Description: BI 3810477 formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3810477
Description: BI 3810477 formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3810477
Description: BI 3810477 formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3810477
Description: BI 3810477 formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3810477
Description: BI 3810477 formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3810477
Description: BI 3810477 formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3810477
Description: BI 3810477 formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3810477
Description: BI 3810477 formulation B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3810477
Description: BI 3810477 formulation B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3810477
Description: BI 3810477 formulation B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05901246

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS-containing dietary supplement
Description: Sachet containing a powdered ingredient source of microencapsulated free plant sterols (2,25 g ingredient/day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sachet containing the excipients of the ingredient (2,25 g placebo/day)
Study: NCT05965440

Intervention type: DRUG
Group type: OTHER
Intervention: impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients
Description: Analysis of microbiota
Study: NCT06086301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PICTURE-THIS
Description: Discharge plans include scheduling post-discharge appointments, community support referrals, transportation arrangements, and addressing identified gaps. Transition care includes 8 check-ins over 3 months post-discharge, focusing on assessing, troubleshooting, and celebrating transition successes, using phone or video. Telehealth-assisted 'warm hand-offs' will connect interventionists with home health and primary care teams during initial visits. '1st touch daytime troubleshooting' offers extra support between check-ins. Problem-solving rehabilitation will be continued from hospital to home, with 7-10 sessions over 3 months, including a home safety survey. A Post-ICU Caregiver Toolkit provides workbooks, training videos, and resources. Lastly, referrals for patient and caregiver social/mental health support are provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced Usual Care (EUC) control group will receive: (1) Patient and Family Re-sources published by the SCCM for PICS prior to hospital discharge; (2) ongoing assessments on the same schedule as the PICTURE-THIS intervention; (3) referral for urgent or emergent issues identified during assessments. The investigators will not provide the URL for the Post-ICU Caregiving Toolkit but the investigators will not restrict its access either. This control design balances 3 goals: 1) masking participants to group allocation; 2) responding ethically to harm/distress; 3) maintaining group separation to optimize efficacy testing of PICTURE-THIS.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Run-In Phase
Description: All participants receive a Run-In Phase during the acute critical illness hospitalization. It consists of 3 inpatient study visits: (1) health and social screening; (2) planning for rehabilitation; (3) discharge education and training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Run-In Phase
Description: All participants receive a Run-In Phase during the acute critical illness hospitalization. It consists of 3 inpatient study visits: (1) health and social screening; (2) planning for rehabilitation; (3) discharge education and training.
Study: NCT05944016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin (standard dose 10 mg p.o. once daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (standard dose p.o. once daily)
Study: NCT05592067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I tape technique
Description: I tape technique described by Dr Kenzo Kase will be applied once a week, a total of 3 times, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Button hole technique
Description: Button hole technique defined by Dr Kenzo Kase will be applied once a week, 3 times in total, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: exercises will be taught to the patient and a total of 21 sessions will be applied once a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: exercises will be taught to the patient and a total of 21 sessions will be applied once a day

Intervention type: OTHER
Group type: OTHER
Intervention: exercises
Description: exercises will be taught to the patient and a total of 21 sessions will be applied once a day
Study: NCT05881980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine Tablets
Description: Terbinafine 250 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine Tablets
Description: Terbinafine 250 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine Tablets
Description: Terbinafine 250 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg/day
Study: NCT06449950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Verbal Oral Hygiene Instructions
Description: OHI-S index scores of patients who received verbal oral hygiene education were measured at baseline and final (in post-education).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Video-Based Oral Hygiene Instructions
Description: OHI-S index scores of patients who received video-based oral hygiene education were measured at baseline and final (in post-education).
Study: NCT05257408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 80 mg/m^2
Description: Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant 150 mg once daily (QD)
Description: Relacorilant is administered as capsules for oral dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel 100 mg/m^2
Description: Nab-paclitaxel is administered as IV infusion on Day 1, 8, and 15 of each 28-day cycle.
Study: NCT05798078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for Interpretation (CBM-I)
Description: The CBM-I intervention is based on the interpretation training paradigm developed by Mathews and Mackintosh (2000). It comprises a series of training scenarios describing different (mostly everyday) socially-relevant situations, structured so they start ambiguously but always have a positive ending. The positive ending is presented as word fragment, which participants are instructure to complete. In about 25% of trials, participants are further requested to respond to comprehension questions about the scenario presented. Each CBM-I session comprises 45 trials presented in 5 blocks of 9 scenarios.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training Control Condition
Description: The sham training is in an identical format to the CBM-I training, except that the scenarios are all entirely neutral, with no reference to social situations and no emotional ambiguity.
Study: NCT06456658

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interruptive Reminder
Description: The reminder will display at the time the chart is opened for eligible patient visits and alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their shopping cart for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-interruptive Reminder
Description: The reminder will have the same format as the interruptive reminder group, but it will not be displayed unless providers seek out the education at their own initiative. The reminder will alert clinicians that a statin is recommended for the patient and list the reasons the statin is indicated. It will give the clinicians a defaulted option for statin prescription as well as alternatives. If the clinician accepts the alert, an order for a statin will be placed in their shopping cart for convenience, and the order can be signed to prescribe the medication. If the clinician does not wish to prescribe a statin from the reminder, they can choose an acknowledgement reason.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Reminder
Description: No reminder recommending a statin will be displayed/available to the provider.
Study: NCT06044337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: Administered as specified in the treatment arm.
Study: NCT05745051

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CVAid Flow
Description: CVA-FLOW is a Telestroke mobile software solution that enables the neurologist to remotely assess, on his smartphone, patients suspected with stroke. Real-time, objective, patient-specific data such as images, videos and vocal records of the patient, are acquired by a first responder (CVA-COLLECTOR) at the patient's location. This allows the neurologist to complete the NIH Stroke Scale and independently reach a diagnostic conclusion and treatment plan (CVA-MED).
Study: NCT05458024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 2
Description: 300,000 international units (IUs) of Ergocalciferol in 6 50,000 IU capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D2 Placebo
Description: Inert substance will be administered in 6 capsules indistinguishable from the 50,000 IU
Study: NCT05874713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N8c on Day 1
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N8c on Day 1
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N6c on Day 1
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N8c on Day 22
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N8c on Day 22
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N6c on Day 22
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N8c on Day 202
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N8c on Day 202
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aH5N8c on Day 202
Description: MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
Study: NCT05275426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2880070
Description: Patients will receive treatment in 21-day cycles with LY2880070 50 mg twice daily orally on days 2-6, 9-13, and 16-20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive treatment in 21-day cycles with gemcitabine 100 mg/m2 intravenously on days 1, 8 and optionally on day 15
Study: NCT05881967

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic biomarker
Description: Diagnostic gene for uterine sarcoma

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic biomarker
Description: Diagnostic gene for uterine sarcoma
Study: NCT05070039

Intervention type: GENETIC
Group type: OTHER
Intervention: Expression of Cortactin anti body
Description: assessment of Cortactin immunohistochemical expression in invasive and non-invasive urothelial carcinoma.
Study: NCT05929560

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional impression
Description: Palatal impressions obtained using an irreversible hydrocolloid impression material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital impression
Description: after obtaining stone models from conventional impression material, stone models were scanned using the I700 (Medit) scanner and Patients were directly scanned intraorally using an intraoral 3D scanner Subsequently, the printed 3D model scan data of the seven patients were then used for standard triangulated language (STL)
Study: NCT05089409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB1651, 2 mg/mL
Description: The participants will apply daily doses of ATB1651, 2 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB1651, 5 mg/mL
Description: The participants will apply daily doses of ATB1651, 5 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB1651, 10 mg/mL
Description: The participants will apply daily doses of ATB1651, 10 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB1651, 20 mg/mL
Description: The participants will apply daily doses of ATB1651, 20 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATB1651, 30 mg/mL
Description: The participants will apply daily doses of ATB1651, 30 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will apply placebo to all 10 toenails including at least 1 affected great toenail for 28 days